top of page
Search


Our researchers develop powerful bispecific inhibitor to combat a wide range of coronaviruses
Researchers from the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT) and the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with Sichuan University, have discovered a powerful bispecific inhibitor capable of combating all existing human-pathogenic coronaviruses, including those resistant to existing treatments like Paxlovid. This promising inhibitor, named TMP1, offers

CVVT
Oct 15


CVVT Showcases Cutting-Edge Innovations at BIOHK2025
Join the Centre for Virology, Vaccinology, and Therapeutics (CVVT) as we unveil cutting-edge advancements in influenza vaccines, liver...

CVVT
Sep 10


CVVT and HKUMed develop innovative organoid-based platform for precise evaluation of antibody and vaccine efficacy, accelerating FDA application of organoid technology
A collaborative research team from CVVT and the Department of Microbiology at the School of Clinical Medicine within the LKS Faculty of...

CVVT
Aug 28
bottom of page
